Jones Erika 4

Accession 0001895913-26-000002

CIK 0001701541other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 4:05 PM ET

Size

5.7 KB

Accession

0001895913-26-000002

AI-generated summary of this filing

Updated Jan 23, 2026

Black Diamond (BDTX) SVP Finance Erika Jones Receives Award

What Happened

Erika Jones, Senior Vice President, Finance and Corporate Controller of Black Diamond Therapeutics (BDTX), received an award on Jan 21, 2026 for 200,000 derivative shares (reported as acquired at $0.00). This filing reports a grant/option award rather than an open-market purchase or sale.

Key Details

Transaction date: January 21, 2026; Form 4 filed January 23, 2026.
Transaction type/code: Award/Grant (derivative) — 200,000 shares @ $0.00.
Vesting: 25% vests and becomes exercisable on January 21, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service (per footnote).
Shares owned after transaction: Not disclosed in the filing.
No immediate exercise or sale reported; this is a grant of an equity award, not a cash transaction.

Context

This is a standard equity award to an executive as part of compensation. It does not represent a purchase or sale of existing shares and does not by itself indicate buying or selling sentiment.
Vesting schedule means the award will only become exercisable over time if the reporting person remains employed.

Form 4

Period: 2026-01-21

SEE REMARKS

Transactions

Award
Stock Option (Right to Buy)
[F1]
2026-01-21+200,000→ 200,000 total
Exercise: $2.57Exp: 2036-01-20→ Common Stock (200,000 underlying)

Footnotes (1)

[F1]25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Brent Hatzis-Schoch, Attorney-in-Fact|2026-01-23

1 file

Black Diamond Therapeutics, Inc.

CIK 0001701541

Entity typeother